• BriaCell Therapeutics (BCT) has entered into definitive securities purchase agreements for gross proceeds of US$27.2 million
  • BriaCell will issue 5,170,343 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock
  • Units are priced at US$5.26. The warrants have a five-and-a-half-year term and an exercise price of US$6.19 per share
  • The placement is expected to close on June 7
  • BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer
  • BriaCell Therapeutics (BCT) is up 4.45 per cent, trading at C$7.74 per share at 11:45 am ET

BriaCell Therapeutics (BCT) has entered into definitive securities purchase agreements for gross proceeds of US$27.2 million.

BriaCell will issue 5,170,343 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock.

Units are priced at US$5.26. The warrants have a five-and-a-half-year term and an exercise price of US$6.19 per share.

This private placement is expected to close on June 7, 2021.

BriaCell is a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer.

BriaCell Therapeutics (BCT) is up 4.45 per cent, trading at C$7.74 per share at 11:45 am ET.

More From The Market Online

Avicanna launches 10% CBD (THC free) formula in Canada

Avicanna (TSX:AVCN) launches RHO Phyto Micro Drop 100, a 10 per cent CBD (THC free), proprietary oral formulation in Canada.

Theratechnologies phases down preclinical oncology research

Biopharmaceutical company Theratechnologies (TSX:TH) announced it will phase down its preclinical oncology research activities.